Bergur V. Stefánsson

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C. Wheeler, Bergur V. Stefánsson, Niels Jongs et al. · The Lancet Diabetes & Endocrinology · 2020 · 530 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson et al. · Kidney International · 2021 · 397 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Intradialytic Hypotension and Risk of Cardiovascular Disease

Bergur V. Stefánsson, Steven M. Brunelli, Claudia Cabrera et al. · Clinical Journal of the American Society of Nephrology · 2014 · 334 citations · Full text

Medicine, Nephrology, Dialysis +14

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow et al. · Nephrology Dialysis Transplantation · 2019 · 216 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17